Related Experiment Video
Updated: Oct 18, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Is metformin use associated with changes in urinary parameters in stone formers?
Daniel C Rosen1, Jacob N Bamberger1, Elie Kaplan-Marans1
1Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Diabetic patients on metformin show altered urinary parameters linked to kidney stone risk, but not significantly different from other diabetic patients. Further research is needed to clarify metformin's role in nephrolithiasis.
Area of Science:
- Nephrology
- Endocrinology
- Metabolic Diseases
Background:
- Diabetes mellitus (DM) increases nephrolithiasis risk.
- Metformin is a common diabetes treatment, but its effect on kidney stone formation is debated.
Purpose of the Study:
- To investigate the association between metformin use and urinary parameters in diabetic patients with kidney stones.
Main Methods:
- Cross-sectional analysis of 505 stone-forming patients.
- Grouped patients by diabetic status and metformin use.
- Evaluated 24-hour urinary parameters and stone type using univariate and multivariate analyses.
Main Results:
- Diabetic patients on metformin had worse urinary parameters, including lower urine pH, compared to non-diabetic patients.
- No significant differences in urinary findings were observed between diabetic patients on metformin and those not on metformin.
Conclusions:
- Diabetic patients on metformin exhibit urinary abnormalities associated with kidney stones.
- Prospective studies are needed to determine metformin's definitive role in nephrolithiasis.
More Related Videos
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi V: Nursing Management
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Oral Hypoglycemic Agents: Biguanides and Glitazones

